Research Papers:

LINE-1 methylation in peripheral blood leukocytes and clinical characteristics and prognosis of prostate cancer patients

Yuyan Han, Junfeng Xu, Jeri Kim, Xifeng Wu and Jian Gu _

PDF  |  HTML  |  How to cite

Oncotarget. 2017; 8:94020-94027. https://doi.org/10.18632/oncotarget.21511

Metrics: PDF 1777 views  |   HTML 2000 views  |   ?  


Yuyan Han1, Junfeng Xu1, Jeri Kim2, Xifeng Wu1 and Jian Gu1

1Department of Epidemiology, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA

2Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA

Correspondence to:

Jian Gu, email: [email protected]

Keywords: LINE-1, methylation, prostate cancer, prognosis

Received: July 06, 2017     Accepted: September 18, 2017     Published: October 04, 2017


Global DNA methylation of long interspersed nucleotide elements (LINE-1) in leukocytes has been suggested to be a risk factor for a few cancers. There has been no report of LINE-1 methylation in leukocytes as a risk factor for aggressive prostate cancer at diagnosis and prognosis after treatments. In this study, we measured the leukocyte DNA methylation of LINE-1 in 795 PCa patients and compared the methylation levels across different clinical subgroups. We then determined the association of LINE-1 methylation in leukocytes with clinicopathological variables at diagnosis using logistic regression analysis and biochemical recurrence in patients receiving active treatments (prostatectomy and radiotherapy) using Cox proportional hazard model after adjusting for age, BMI, smoking status, pack year, D’Amico risk groups, and treatments. Overall, the DNA methylation of LINE-1 was not associated with the risk of being diagnosed with high-risk prostate cancer or the risk of biochemical recurrence upon active treatments. Future studies are warranted to investigate other types of repetitive element methylation and longitudinal changes of global methylation in relation to prostate cancer risk and prognosis.

Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 21511